4.6 Meeting Abstract

Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes

Journal

JOURNAL OF THORACIC ONCOLOGY
Volume 13, Issue 4, Pages S72-S73

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S1556-0864(18)30402-7

Keywords

-

Funding

  1. AstraZeneca

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available